Loading
Lenvatinib matched sorafenib for survival in advanced liver cancer while shrinking tumours far more often and delaying progression longer, making it the first new first-line option in ten years.
Phase 3 non-inferiority trial of 954 patients with unresectable hepatocellular carcinoma randomised to lenvatinib (weight-based 8 or 12 mg) or sorafenib.
Median overall survival was 13.6 versus 12.3 months (hazard ratio 0.92, non-inferior), progression-free survival 7.4 versus 3.7 months, and response 24.1 versus 9.2 percent; hypertension, proteinuria and decreased appetite were more frequent with lenvatinib.
Lenvatinib is a first-line alternative to sorafenib and the preferred kinase inhibitor when immunotherapy is contraindicated, such as after liver transplantation.
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C), Lenvatinib.
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C).
Shares Sorafenib, The Lancet.
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C).
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib.
Shares Lenvatinib, The Lancet.
Shares Advanced hepatocellular carcinoma (BCLC C), Lenvatinib.
Shares Sorafenib, Advanced hepatocellular carcinoma (BCLC C).